Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 million worth of stock in the aftermath of the selloff.
Trending
- Why 26% of Americans Are Living Beyond Their Means
- Microsoft Is Testing Another Awful Campaign To Get Chrome Users To Move To Edge
- If you’re feeling FOMO, envy and greed about record stock prices, you’re not alone. It’s how market bubbles form.
- Trump-Era Regulations Will Ease Access to Crypto
- Sam Altman Worries About AI’s Impact on Older Workers
- These 2 AI stocks will outperform Palantir over the next year, according to analysts
- ChatGPT’s model picker is back, and it’s complicated
- USPS Is Raising Prices for Holiday Shipping: Dates and Increases You Need to Know
